ATSP-7041

General Information


DRACP ID  DRACP05906

Peptide Name   ATSP-7041

Sequence  LTFⓍEYWAQXⓍSAA

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Stapled Peptides Induce apoptosis MDM2/MDMX Inhibitor



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  MDM2, MDMX

Affinity  MDM2: Ki=0.9 nM; MDMX: Ki=6.8 nM

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ(4) and Ⓧ (11) are cross-linked by hydrocarbon stapling

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  Ⓧ(4)=R8; Ⓧ(11)=S5; X=Cba

Chiral  L



Physicochemical Information


Formula  C61H77N13O15

Absent amino acids  CDGHIKMNPRV

Common amino acids  A

Mass  157442

Pl  3.85

Basic residues  0

Acidic residues  1

Hydrophobic residues  6

Net charge  -1

Boman Index  -280

Hydrophobicity  9.29

Aliphatic Index  49.29

Half Life 
  /

Extinction Coefficient cystines  6990

Absorbance 280nm  537.69

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23946421

Title  Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Doi 10.1073/pnas.1303002110

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.